Search

In the present study, we compared estimates of split renal function (SRF) in paediatric patients of various diagnostic subgroups by 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy using either geometric mean (GM) based on planar scans or a volume of interest (VOI)-based analysis on single photon emission tomography combined with low-dose CT (SPECT/ldCT). Two experienced physicians blinded to patient diagnosis retrospectively analysed all paediatric 99mTc-DMSA scintigraphies that were conducted in our department between 2011 and 2016 and which included both a planar scan and SPECT/ldCT. All scintigraphies were performed on either a Phillips Precedence 16 slice CT or a Siemens Symbia 16 slice CT. SRF was estimated from planar scintigraphy using the geometric mean (GM), while the VOI-based analysis (VBA) was used for kidney segmentation on SPECT/ldCT. RESULTS: A total of 68 scintigraphies were included. A Bland-Altman plot-based analysis showed a bias for SRF of 2.1% with limits of agreement from - 7.5 to + 11.7% for the whole data set but showed larger differences between the two methods outside the normal range of 45-55%. In the GM-based SRF analyses, 29 cases were found to be outside the normal range, and in seven of these, VBA showed normal SRF. In the remaining 39 cases, VBA showed an abnormal SRF in only one case. CONCLUSION: Approximately a quarter of planar DMSA scintigraphies that show an abnormal SRF in paediatric patients may be normal when assessed by SPECT/ldCT, which likely reflects underestimation of the kidney with the poorest function when assessed by GM due to the lack of attenuation correction. Planar scans that show an abnormal SRF in paediatric patients should thus preferably be supplemented by SPECT/ldCT.

Supplemental Digital Content is available in the text., Introduction Ventilation and perfusion single-photon emission computed tomography combined with computed tomography (SPECT/CT) is a powerful tool to assess the state of the lungs in chronic obstructive pulmonary disease (COPD). 81mKrypton is a gaseous ventilation tracer and distributes similarly to air, but is not widely available and relatively expensive. 99mTc-Technegas is cheaper and has wider availability, but is an aerosol, which may deposit in hot spots as the severity of COPD increases. In this study, 81mKrypton and 99mTc-Technegas were compared quantitatively in patients with severe COPD. Methods The penetration ratio, the heterogeneity index (with and without band filtering for relevant clinical sizes) and hot spot appearance were assessed in eleven patients with severe COPD that underwent simultaneous dual-isotope ventilation SPECT/CT with both 99mTc-Technegas and 81mKrypton. Results Significant differences were found in the penetration ratio for the medium energy general purpose (MEGP) collimators, but not for the low energy general purpose (LEGP) collimators. The difference in the overall and the band filtered heterogeneity index was significant in most cases. All patients suffered from 99mTc-Technegas hot spots in at least one lung. Comparison of MEGP 81mKrypton and LEGP Technegas scans revealed similar results as the comparison for the MEGP collimators. Conclusion Caution should be taken when replacing 81mKrypton with 99mTc-Technegas as a ventilation tracer in patients with severe COPD as there are significant differences in the distribution of the tracers over the lungs. Furthermore, this patient group is prone to 99mTc-Technegas hot spots and might need additional scanning if hot spots severely hamper image interpretation.

Purpose Patient-specific dosimetry of lutetium-177 (177Lu)-DOTATATE treatment in neuroendocrine tumours is important, because uptake differs across patients. Single photon emission computer tomography (SPECT)-based dosimetry requires a conversion factor between the obtained counts and the activity, which depends on the collimator type, the utilized energy windows and the applied scatter correction techniques. In this study, energy window subtraction-based scatter correction methods are compared experimentally and quantitatively. Materials and methods 177Lu SPECT images of a phantom with known activity concentration ratio between the uniform background and filled hollow spheres were acquired for three different collimators: low-energy high resolution (LEHR), low-energy general purpose (LEGP) and medium-energy general purpose (MEGP). Counts were collected in several energy windows, and scatter correction was performed by applying different methods such as effective scatter source estimation (ESSE), triple-energy and dual-energy window, double-photopeak window and downscatter correction. The intensity ratio between the spheres and the background was measured and corrected for the partial volume effect and used to compare the performance of the methods. Results Low-energy collimators combined with 208 keV energy windows give rise to artefacts. For the 113 keV energy window, large differences were observed in the ratios for the spheres. For MEGP collimators with the ESSE correction technique, the measured ratio was close to the real ratio, and the differences between spheres were small. Conclusion For quantitative 177Lu imaging MEGP collimators are advised. Both energy peaks can be utilized when the ESSE correction technique is applied. The difference between the calculated and the real ratio is less than 10% for both energy windows.

OBJECTIVE: One of the main problems in quantification of single photon emission computer tomography imaging is scatter. In iodine-123 (I-123) imaging, both the primary 159 keV photons and photons of higher energies are scattered. In this experimental study, different scatter correction methods, based on energy window subtraction, have been compared with each other. METHODS AND MATERIALS: Iodine-123 single photon emission computed tomography images of a phantom with a known intensity ratio between background and hollow spheres were acquired for three different collimators (low energy high resolution, low energy general purpose, and medium energy general purpose). The hollow spheres were filled with a higher activity concentration than the uniform background activity concentration, resulting in hot spots. Counts were collected in different energy windows, and scatter correction was performed by applying different methods such as effective scatter source estimation, triple and dual energy window (TEW and DEW), double peak window (DPW) and downscatter correction. The intensity ratio between the spheres and the background was used to compare the performance of the different methods. RESULTS: The results revealed that the efficiency of the scatter correction techniques vary depending on the collimator used. For the low energy high resolution collimator, all correction methods except the effective scatter source estimation and the DPW perform well. For the medium energy general purpose collimator, even without scatter correction, the calculated ratio is close to the real ratio. The DEW and DPW methods tend to overestimate the ratio. For the low energy general purpose collimator, only the DEW and the combined DEW and downscatter correction methods perform well. CONCLUSION: The only correction method that provides a ratio that differs by less than 5% from the real ratio for all the collimators is the combined DEW and downscatter correction method.

Purpose Multi-centre trials are an important part of proving the efficacy of procedures, drugs and interventions. Imaging components in such trials are becoming increasingly common; however, without sufficient control measures the usefulness of these data can be compromised. This paper describes a framework for performing high-quality multi-centre trials with single photon emission computed tomography (SPECT), using a pan-European initiative to acquire a normal control dopamine transporter brain scan database as an example. Methods A framework to produce high-quality and consistent SPECT imaging data was based on three key areas: quality assurance, the imaging protocol and system characterisation. Quality assurance was important to ensure that the quality of the equipment and local techniques was good and consistently high; system characterisation helped understand and where possible match the performance of the systems involved, whereas the imaging protocol was designed to allow a degree of flexibility to best match the characteristics of each imaging device. Results A total of 24 cameras on 15 sites from 8 different manufacturers were evaluated for inclusion in our multi-centre initiative. All results matched the required level of specification and each had their performance characterised. Differences in performance were found between different system types and cameras of the same type. Imaging protocols for each site were modified to match their individual characteristics to produce comparable high-quality SPECT images. Conclusion A framework has been designed to produce high-quality data for multi-centre SPECT studies. This framework has been successfully applied to a pan-European initiative to acquire a healthy control dopamine transporter image database

In nuclear medicine brain imaging, it is important to delineate regions of interest (ROIs) so that the outcome is both accurate and reproducible. The purpose of this study was to validate a new time-saving algorithm (DATquan) for accurate and reproducible quantification of the striatal dopamine transporter (DAT) with appropriate radioligands and SPECT and without the need for structural brain scanning. Methods: In a reconstructed DAT SPECT image, DATquan automatically calculated the ratio at steady state of specifically bound radioligand to nondisplaceable radioligand in tissue (BPND) within striatal ROIs that were delineated by use of a semiautomatic template-based alignment approach. DATquan was tested with 123 I-N-(3-iodoprop2E-enyl)-2-b-carbomethoxy-3b-(4-methylphenyl) SPECT images from 15 patients. In each image, ROIs were first manually delineated, and then corresponding BPND values were derived by an experienced physician. Afterward, 2 independent novice operators used DATquan to analyze the same 15 images. The resulting DATquan-derived BPND data were compared with the data retrieved by manual delineation to assess the accuracy and reproducibility of DATquan. Also, the operational aspects of DATquan were assessed on the basis of measurements of the mean running time of the algorithm as well as on the basis of quantification of the overlap of the DATquandelineated ROIs obtained by the 2 operators. Results: The mean algorithm running time was 3 min, and the operators’ striatal ROIs had a mean overlap of more than 82%. DATquanderived BPND values obtained by the 2 operators showed high agreement (the mean difference was 0.00 [SD, 0.05] in the striatum, 0.02 [SD, 0.26] in the putamen, and 0.03 [SD, 0.43] in the caudate nucleus). The interoperator variability was 2.2% (SD, 1.3%) in the striatum, 11.7% (SD, 9.9%) in the putamen, and 12.9% (SD, 4.0%) in the caudate nucleus. DATquan-derived BPND values showed high agreement with the values manually derived by the experienced delineator. Conclusion: DATquan is a freely available, accurate, and highly reproducible method for quantification of DAT binding in the brain by SPECT. Once implemented in clinics, DATquan will serve as a useful and time-saving tool.

A particularly sensitive step in the quantification of SPECT images of the dopamine transporter (DAT) is a correct delineation of the region of interest (ROI). In this study, we primarily compared the reproducibility of the following different approaches for ROI delineation in SPECT images of the DAT: the use of manual delineation (MD) on high-count striatal slides directly on the SPECT image, ROI delineation based on individual MR images (MRD), and oversized striatal ROIs—that is, the striatal volume of interest (SVI), as described previously. We also assessed the ability of the different approaches to identify striatal pathology in patients with parkinsonism. Methods: Eight patients with highly variable reductions in cerebral DAT availability were SPECT-scanned twice with 123I-labeled N-(3-iodoprop-(2E)-enyl)-2β-carboxymethoxy-3β-(4′-methylphenyl) nortropane bolus infusion setup and once with an MRI scanner. For SPECT/MRI coregistration, we used external fiducial markers visible on both MRI and SPECT. With the MD and MRD methods, the outcome parameters for DAT availability were the binding potentials and the ratio at equilibrium of specifically bound radioligand to nondisplaceable radioligand in tissue (BPND). For the SVI method, the outcome parameter was the specific binding ratio (SBR). Results: No statistically significant difference in striatal BPND intraobserver reproducibility was seen among any of the 3 methods. The intraobserver reproducibility average ± SD for MD was 7.0% ± 4.1%; for MRD, 5.7% ± 5.4%; and for SVI, 6.7% ± 6.0%. Mean intrasubject variability, as determined from the test–retest scans, did not differ with the 3 delineation methods used. The average (±SD) intrasubject variability of striatal BPND was 11.9% ± 10.0% with MD and 14.6% ± 15.3% with MRD. With the SVI method, the intrasubject variability of striatal specific binding ratio was 10.0% ± 10.2%. BPND values obtained with the MD and MRD methods were similar (paired t test, P > 0.4). Conclusion: In patients with reduced striatal DAT binding, the reproducibility of the outcome from ROI MD is comparable to both that obtained by delineation of ROI on individual MR images, followed by coregistration to the SPECT image, and that obtained with the SVI-based approach.

The purpose of our study was to use the total choline-containing compound (tCho) peak integral as a marker of malignancy in breast MR spectroscopy (MRS).Forty-eight single-voxel water- and fat-suppressed 1.5-T MRS measurements were performed in 42 patients, obtaining both absolute tCho peak integral and tCho peak integral normalized for the volume of interest (VOI). Our reference standard was histology for lesions with BI-RADS category 4 and 5 and histology or at least a 2-year follow-up for findings with BI-RADS 2 and 3 and normal glands. Receiver operating characteristic (ROC) analysis, Mann-Whitney U test, and Spearman's rank correlation were used.Three of 48 measurements (6%) failed. Of the remaining 45 spectra, 18 nonmalignant tissues showed no tCho peak, eight nonmalignant tissues showed a tCho peak integral from 0.99 to 9.03 arbitrary units (AU), and 19 malignant lesions showed a tCho peak integral from 1.26 to 19.80 AU. The diameter of nonmalignant tissues was 16.9 +/- 7.4 mm; that of malignant lesions was 15.3 +/- 6.9 mm (p = 0.308). At ROC analysis, the optimal threshold was 1.90 AU for absolute tCho peak, with 0.895 (17/19) sensitivity, 0.923 (24/26) specificity, and an AUC (area under the curve) of 0.917 (95% CI, 0.822-1.000); the optimal threshold was 0.85 AU/mL for the normalized tCho peak integral with 0.842 (16/19) sensitivity, 0.885 (23/26) specificity, and an AUC of 0.941 (0.879-1.000) (p = 0.470). A negative correlation (p = 0.011) was found between the VOI and the normalized tCho peak integral of malignant tissues.Breast MRS using tCho peak integral reaches a high level of diagnostic performance.

The iodinated cocaine derivative [(123)I]PE2I is a new selective ligand for in vivo studies of the dopamine transporter (DAT) with SPECT. Recently, a bolus/infusion (B/I) protocol for [(123)I]PE2I measurements of DAT density was established [Pinborg LH et al. J Nucl Med 2005;46:1119-271]. The aims of this study were, firstly, to evaluate the test-retest variability using the B/I protocol and, secondly, to evaluate the B/I approach in a new group of healthy subjects using two outcome parameters, BP(1) (C(ROI)/C(plasma)) and BP(2) (C(ROI)/C(REF)).Seven healthy subjects were subjected to [(123)I]PE2I SPECT scanning twice. For both studies, the two outcome parameters BP(1) and BP(2) were calculated based on two different methods for region of interest (ROI) delineation, namely manual delineation and probability map-based automatic delineation with MRI co-registration.With manual delineation, striatal test-retest variability (absolute difference between first and second scan as a percentage of the mean) of BP(1) and BP(2) was 13.9% (range 1.8-35.7%) and 4.1% (range 0.5-9.7%) respectively. The probability map-based automatic delineation resulted in striatal test-retest variability of 17.2% (range 4.3-40.5%) and 5.2% (range 0.1-10.9%) respectively. The B/I approach provided stable brain activity from 120 to 180 min post injection in both high- and low-count regions with a mean % change/hour in striatal BP(2) of 10.6.[(123)I]PE2I SPECT with the B/I approach yields a highly reproducible measure of striatal dopamine transporter binding. The appropriateness of a B/I protocol with a B/I ratio of 2.7 h (i.e. with a bolus worth 2.7 h of infusion) was confirmed in an independent sample of healthy subjects.

Purpose A joint initiative of the European Association of Nuclear Medicine (EANM) Neuroimaging Committee and EANM Research Ltd. aimed to generate a European database of [123I]FP-CIT single photon emission computed tomography (SPECT) scans of healthy controls. This study describes the characterization and harmonization of the imaging equipment of the institutions involved.

Functional brain (99m)Tc-HMPAO single-photon emission computed tomography (SPECT) is a useful diagnostic tool for assessment of regional cerebral blood flow, particularly in dementia, cerebrovascular disease and epilepsy. Currently, the European and American Association of Nuclear Medicine Procedure Guidelines for Brain Perfusion SPET using (99m)Tc-labeled Radiopharmaceuticals recommend a time delay of 90 min between injection of (99m)Tc-HMPAO and data acquisition. This time delay is difficult to comply within the daily routine and present a problem, particularly with the elderly or demented patients. This study investigates in patients with perfusion deficits and in healthy subjects if the quality of the SPECT image is affected by lowering the time delay between (99m)Tc-HMPAO injection and data acquisition to 30 or 60 min.Thirty-seven healthy subjects (17 females; mean age 65; range 42-84 years) with normal cerebral blood flow distribution and 31 patients (17 females; mean age 67; range 38-84) with reduced rCBF distribution were included. Images were obtained with a three-headed Philips IRIX SPECT scanner with high-resolution collimators. The healthy subjects were scanned 30, 60 and 90 min after (99m)Tc-HMPAO injection, and the patients were scanned 30 and 90 or 60 and 90 min after (99m)Tc-HMPAO injection. For evaluation of differences between the images obtained at various time points after injection, two different methods were used. The z-map method was used to subtract images from each other prior to visual inspection. In addition, principal component analysis was used as a quantitative analysis of the similarity of the images.Visual inspection of the subtracted images (30 or 60 versus 90 min) revealed that there was no spatial bias. Quantitatively, the average proportion of the total variance explained by the first principal component was 99.5% (range 98.9-99.6) for the healthy subjects and 99.4% (range 98.5-99.8) for the patients.The time delay from injection of (99m)Tc-HMPAO to the start of the SPECT data acquisition can be reduced from 90 to 30 min without any significant impact on the quality of the acquired image.